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and Andres Beiras-Fernandez1*Abstract
A 48 year old patient with dilated cardiomyopathy and chronic acne inversa underwent implantation of a LVAD
system (Heartmate II, Thoratec, USA) March 2011. During 2011 and 2012 the patient was repeatedly readmitted for
treatment of driveline infection with MRSA. Colonization was controlled with Linezolid and Rifampicin however
reoccurred after discontinuation. In August 2012 the LVAD-system was exchanged due to pump dysfunction (HVAD,
HeartWare Inc., USA). Postoperatively, the patient presented with ascites which secreted through the driveline exit.
Consequently, the abdominal wall was surgically corrected to prevent exit of peritoneal fluid through the driveline,
and the patient was discharged with sterile wound swabs. However 6 weeks after discharge the driveline exit wound
started secreting pus showing abundant growth of multi resistant staphylococcus aureus (MRSA). With clinical signs of
increasing liver failure with regular need for paracentesis, and clinical signs of local infection, a CT scan of the abdomen
was performed revealing an enrichment of contrast medium along the driveline and an abscess-like formation on the
abdominal wall. Patient was admitted receiving regular dose Daptomycin and Rifampicin. The latter was discontinued
after ten days. The abscess, surrounding driveline exit and abdominal wall cavity was excised and vacuum treatment
initiated. Total duration of Daptomycin therapy was 3 weeks. While first week skin and wound swabs were still positive
for MRSA, all samples were sterile after the second week. Inflammation was monitored by leucocyte count and IL6. The
secretion of pus along the driveline ceased, the wound cavity was closed subsequently. After discharge and stop of
antibiotics skin and driveline swabs remained negative for MRSA (10 weeks).
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Left ventricular assist device (LVAD) implantation is not
only a bridge-to-transplantation option for patients await-
ing a donor heart, but is often used as bridge-to-destination
therapy in patients unsuitable for transplantation for vari-
ous reasons. Device infection remains a threatening com-
plication, which may lead to prolonged hospitalisation,
need to device exchange, urgent transplantation, and even
death of the patient [1]. Infections with multidrug resistant
(MDR) organisms pose major difficulties for eradication
therapy. Especially patients who are subject to continuous
hospital treatments risk contamination or change of
resistances spectrum. Gold standard therapy of certain* Correspondence: Andres.Beiras@kgu.de
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unless otherwise stated.organisms often fails to eradicate surface associated
colonisations of implanted devices such as cardiovascular
implants, while failed eradication leads to numerous
complications and an increased mortality rate among the
affected patients. Device infections through multidrug
resistant bacteria, such as MRSA, are often resistant even
to first-line antibiotics, due to extended resistance spec-
trum and reduce tissue penetration in scar tissue after
multiple surgical procedures. In addition a solid biofilm
on devices is often impenetrable even for suitable antibi-
otics because of the isolating nature of biofilms [1-3].
Daptomycin is a cyclic lipopeptide with excellent bac-
tericidal efficacy especially upon infections of skin and
soft tissue where last resort antibiotics like Linezolid and
Vancomycin fail. A synergistic action of Rifampicin and
Daptomycin for the treatment of MDR organisms has
been previously reported [4].Ltd. This is an Open Access article distributed under the terms of the Creative
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who 6 months after redo implantation of a LVAD present-
ing with a chronic driveline infection with MRSA. This
patient was treated successfully with a combination of
surgical wound management and antibiotic treatment
based on Daptomycin and Rifampicin.
Case presentation
In March 2011 a 48 year old patient (male, caucasian) with
dilated cardiomyopathy, congestive heart failure, chronic
liver and kidney failure, and a chronic condition of acne
inversa underwent an implantation of an LVAD system
(Heartmate II, Thoratec, USA) due to rapid cardiopulmo-
nary deterioration. At the time of the implantation, the
velour surrounding the driveline was partly exteriorized
to provide better connection with the surrounding tissue.
Initially a right ventricular assist device (RVAD) was
implanted in extra corporal oxygenation mode (ECMO).
After cardiopulmonary stabilisation the ECMO was ex-
planted on postoperative day 6. The patient was discharged
into rehabilitation after further clinical stabilisation. During
2011 and 2012 the patient was repeatedly readmitted for
treatment of driveline infections with MRSA. Initially
treated with Linezolid and Rifampicin as antibiotic therapy,
the colonization could only be controlled under antibiotic
therapy and reoccurred after discharge. Skin and surface
swabs of the VAD system showed growth of MRSA be-
tween clinical stays. With this patient, the LVAD therapy
was considered a bridge-to-destination therapy, both
because of lack of compliance regarding smoking and
nutrition and because of a severe cirrhosis cardiaque
possibly combined with nutritive liver cirrhosis that made
a simultaneous liver transplantation necessary.
In August 2012 a rapid deterioration of the patient’s
health condition led to the diagnosis of LVAD dysfunction
with bacterial superinfection of the pump system and
severe pneumonia. At admission anticoagulation was suffi-
cient, even slightly above the INR ratio requested for
LVAD function because of ongoing liver failure. Neverthe-
less a DIC (disseminated intravascular coagulation) associ-
ated with the septic state might have led to clot formation
inside the VAD system. A solid bacterial biofilm inside the
LVAD pump was discussed a reason for system failure.
Listing for high urgent transplantation was dismissed.
Not only there was a need to perform a combined heart
and liver transplantation because of acute-on-chronic
liver failure but also the highly unstable cardiopulmo-
nary situation of the patient with multi organ failure did
not permit such an extensive operation by means of a
possible negative outcome on postoperative morbidity
and mortality.
Because of therapy resistant output failure despite
increasing doses of catecholaminergic support an arterio-venous ECMO was implanted prior to redo surgery. To
assess cardiac function before redo surgery numerous
transoesophageal echocardiograms were conducted, show-
ing a global strongly impaired ventricular function and
insufficiency of the AV valves, but no sign of endocarditis.
After implantation of a new LVAD system (HVAD; Heart-
Ware Inc., USA) and prolonged stay in the intensive care
unit the patient recovered. Implantation of a HeartWare
LVAD system was chosen because of a thinner driveline
with a shorter velour sleeve that does not exit the wound.
Also the patient had suffered from chronic left sided thor-
acic pain located at the site of the former LVAD pump.
Because of the pump size and its position in the thoracic
cavity the pump was always in very close vicinity to the
ribcage, almost penetrating through the intercostal muscle
layer. A better fit could be achieved at redo implantation
with the smaller HeartWare pump.
The presumably infected LVAD system was completely
removed, including extirpation of the velour sheet around
the driveline and extensive surgical debridement of the
surrounding scarred subcutaneous tissue.
During his stay, the patient developed ascites with a
need for regular paracentesis (once per week). Secretion
of peritoneal fluid through the driveline exit wound
was observed. A surgical intervention to tighten the exit
channel of the driveline was successfully performed. The
patient was discharged into ambulatory treatment on day
35 following redo surgery.
While wound swabs during the hospitalisation period
showed no bacterial growth even after discontinuation
of antibiotics soon after discharge the driveline exit
wound started secreting pus. All wound swabs showed
abundant growth of MRSA, but also regular skin swabs
showed growth of MRSA. In order to find a possible
source for reinfection with MRSA household members
of the patient were checked for MRSA, but with no posi-
tive result.
Because of increasing liver failure with regular need for
ambulatory paracentesis as well a local signs of infection a
CT scan of the abdomen was performed. The CT scan
showed an enrichment of contrast medium along the
driveline, especially in the superficial parts close to the
exit wound as well as an abscess-like formation on the
abdominal wall. A sample that was obtained from this
formation by ultrasound-guided puncture was also posi-
tive for MRSA (Figure 1). The patient was readmitted
to receive an antibiotic regime of intravenous (i.v.)
Daptomycin and Rifamipcin, both applied in regular dose.
Rifampicin was discontinued ten days after initiation of
therapy due to the pre-existent liver dysfunction of the
patient. Additionally surgical exstirpaton of the abscess and
the tissue surrounding the driveline exit were performed,
including all parts of velour that were accessible to opera-
tive debridement. Vacuum wound treatment (VAC system,
Figure 1 CT-scan of abdominal abscess formation (circles), A-Axial view; B-Sagittal view.
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the site of the excised abscess.
The total duration of Daptomycin therapy exceeded
3 weeks (24 days). During the first week skin and wound
swabs were still positive for MRSA however after the
second week all samples remained sterile. All samples
were obtained under antibiotic therapy during the hospital
stay. Inflammation parameters were monitored through
leucocyte count and Interleukine 6 (IL6). Secretion of pus
along the driveline was never observed after operative
debridement, the remaining abscess cavity was closed
subsequently. Leucocyte count and IL6 returned to normal
values. After discharge and discontinuation of antibiotic
therapy skin and driveline swabs remained negative for
MRSA (Figure 2). The patient had to appear weekly at the
outpatient clinic of the cardiothoracic department. At each
visit blood samples, skin and wound swabs were obtained,
and a clinical examination with focus on the wound condi-
tion was performed. The patient remained negative for
MRSA at 6 months follow-up. For follow-up of the cardiac
condition ultrasound examinations were performed regu-
larly during the entire follow-up.
Discussion
Device infections with MDR organisms still pose a major
threat, with alternatives for surgical treatment being limitedFigure 2 Skin condition following treatment. Notice normal scar
formation (arrows) without any signs of inflammation.to device exchange of local debridement in less severe
cases. Device exchange however has a high rate of mortal-
ity, as the patients in need of device exchange are often
subject to multiple comorbidities and usually in a septic
or sub-septic state at time of device exchange [1,4].
As with all implanted cardiac devices, device endocar-
ditis is considered to be one of the most challenging
complications. While conservative treatment of a colo-
nized LVAD system may be successful, focus removal of
infected valves becomes far more complicated when after
failed conservative treatment neither valve function nor
organ function can be restored without surgical interven-
tion. Floating vegetations can also lead to embolisation
and pump dysfunction when sucked into the inflow
cannula of the VAD system, apart from leading to organ
embolisation. Therefore it is vital to perform thorough
echocardiogram examinations on patients in risk of LVAD
endocarditis when device infection is suspected.
Antibiotic treatment of MRSA infections proved to
become increasingly difficult, with strains of MRSA
with intermediate efficacy for Vancomycin and other
last resort antibiotics, or even fully resistant strains [3].
For these highly specific infections Daptomycin has
proved to be an effective treatment [1,4,5]. To prevent
prolonged hospitalisation and need for device exchange,
we recommend an aggressive antibiotic therapy with Dap-
tomycin combined with local debridement and vacuum
treatment in infected wound cavities. In addition to
this, after patient discharge, regular follow-up visits with
trained staff familiar with LVAD treatment are necessary
to detect reoccurrence of any infection. Prolonged anti-
biotic therapy can be applied in cases without local tissue
complications and should be treated as aggressive as a
non-native-valve endocarditis, preferably in cooperation
with the infectiology department.
In this case we conclude that i.v. application of Dapto-
mycin is a sufficient and effective therapy in eradication
of colonization with multidrug-resistant organisms. There
have been several cases of successfully eradicated MRSA
or other MDR-organism infected patients, yet all cases
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of similar cases in one hospital should be obtained to gain
further insight of the dynamics involved in eradication of
MDR organisms with Daptomycin.
Conclusions
In the present case we showed that successful eradication
of a chronic LVAD driveline infection with MRSA in our
patient was only possible when approached both surgically
and conservatively. It is important to point out that while
this was a single case study, conclusions towards broader
applications can still be drawn from it. Especially in
patients with several comorbidities that suffer from chronic
infections of non-native material, a similar aggressive
approach for eradication can be attempted in order to
avoid even more aggressive redo operations.
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